Counseling Points - January 2009 - (Page 12)

12. Vitiellio B. Understanding the risk of using medications for attention deficit hyperactivity disorder with respect to physical growth and cardiovascular function. Child Adolesc Psychiatr Clin N Am. 2008;17:459-474. 13. Zachor DA, Roberts AW, Hodgens JB, et al. Effects of long-term psychostimulant medication on growth of children with ADHD. Res Dev Disabil. 2006;27:162-174. 14. Gadow KD, Sverd J, Sprafkin J, et al. Long-term methylphenidate therapy in children with comorbid attention-deficit hyperactivity disorder and chronic multiple tic disorder. Arch Gen Psychiatry. 1999;56:330-336. 15. Dexedrine® Package Insert. Accessed 12/13/08 at http://us.gsk.com/ products/assets/us_dexedrine.pdf. 16. Perrin JM, Friedman RA, Knilans TK, et al. Cardiovascular monitoring and stimulant drugs for attention-deficit/hyperactivity disorder. Pediatrics. 2008;122:451-453. 17. Kratochvil CJ, Heiligenstein JH, Dittmann R, et al. Atomoxetine and methylphenidate treatment in children with ADHD: a prospective, randomized, open-label trial. J Am Acad Child Adolesc Pschiatry. 2002;41: 776-784. 18. Spencer TJ, Sallee FR, Gilbert DL, et al. Atomoxetine treatment of ADHD in children with comorbid Tourette syndrome. J Atten Disord. 2008;11: 470-481. 19. Wolraich ML, Wibbelsman CJ, Brown TE, et al. Attention-deficit/hyperactivity disorder among adolescents: A review of diagnosis, treatment, and clinical implications. Pediatrics. 2005;115:1734-1746. 20. Bangs ME, Tauscher-Wisniewski S, Polzer J, et al. Meta-analysis of suiciderelated behavior events in patients treated with atomoxetine. J Am Acad Child Adolesc Psychiatry. 2008;47:209-218. 21. Davis W, Bentivoglio P, Racusin R, et al. Bupropion SR in adolescents with combined attention deficit hyperactivity disorder and depression. J Am Acad Child Adolesc Psychiatry. 2001;40:307-314. 22. Fuller M, Sajatovic M. Drug Information Handbook for Psychiatry. Fourth Edition. Hudson, Oh: Lexi-Comp. 2004. 23. Greenhill LL, Abikoff HB, Arnold LE, et al. Medication treatment strategies in the MTA study: relevance to clinicians and researchers. J Am Acad Child Adolesc Psychiatry. 1996;35:1304-1313. 24. Kelsey DK, Sumner CR, Casat CD, et al. Once-daily atomoxetine treatment for children with attention-deficit/hyperactivity disorder, including an assessment of evening and morning behavior: A double-blind, placebocontrolled trial. Pediatrics. 2004;114:e1-8. 25. Greenhill LL, Pliszka S, Dulcan MK, et al. Practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults. J Am Acad Child Adolesc Psychiatry. 2002;41:26S-49S. 26. Committee on Quality Improvement, Subcommittee on AttentionDeficit/Hyperactivity Disorder. Clinical practice guideline: Diagnosis and evaluation of the child with attention-deficit/hyperactivity disorder. Pediatrics. 2000;105:1158-1170. 27. Hughes CL, Emslie GJ, Crismon ML, et al. The Texas Children’s Medication Algorithm Project: Report of the Texas Consensus Conference Panel on Medication Treatment of Childhood Major Depressive Disorder. J Am Acad Child Adolesc Psychiatry. 1999;38:1442-1454. 28. Emslie GJ, Hughes CW, Crismon ML, et al. A feasibility study of the childhood depression medication algorithm: the Texas Children’s Medication Algorithm Project (CMAP). J Am Acad Child Adolesc Psychiatry. 2004;43: 519-527. 29. Frazier JA, Biederman J, Tohen M, et al. A prospective open-label treatment trial of olanzapine monotherapy in children and adolescents with bipolar disorder. J Child Adolesc Psychopharmacol. 2001;11:239-250. 30. Madaan V, Chang KD. Pharmacotherapeutic strategies for pediatric bipolar disorder. Expert Opin Pharmacother. 2007;8:1801-1819. 31. Tint A, Haddad PM, Anderson IM. The effect of rate of antidepressant tapering on the incidence of discontinuation symptoms: A randomized study. J Psychopharmacol. 2008;22:330-332. 32. Kaizar EE, Greenhouse JB, Seltman H, Kelleher K. Do antidepressants cause suicidality in children: A Bayesian meta-analysis. Clin Trials. 2006;3:73-90. 33. Pliszka SR, Greenhill LL, Crismon ML, et al. The Texas Children’s Medication Algorithm Project: Report of the Texas Consensus Conference Panel on Medication Treatment of Childhood Attention-Deficit/Hyperactivity Disorder, part I. J Am Acad Child Adolesc Psychiatry. 2000;39:908-919. 34. Kratochvil CJ, Newcorn JH, Arnold LE, et al. Atomoxetine alone or combined with fluoxetine for treating ADHD with comorbid depressive or anxiety symptoms. J Am Acad Chil Adolesc Psychiatry. 2005;44:915-924. 35. Abikoff H, McGough J, Vitiello B, et al. Sequential pharmacotherapy for children with comorbid attention-deficit/hyperactivity and anxiety disorders. J Am Acad Child Adolesc Psychiatry. 2005;44:418-427. 36. Clark DB, Birmaher B, Axelson D, et al. Fluoxetine for the treatment of childhood anxiety disorders: open-label, long-term extension to a controlled trial. J Am Acad Child Adolesc Psychiatry. 2005;44:1263-1270. 37. Wagner KD, Berard R, Stein MB, et al. A multicenter, randomized, doubleblind, placebo-controlled trial of paroxetine in children and adolescents with social anxiety disorder. Arch Gen Psychiatry. 2004;61:1153-1162. 38. Singh MK, DelBello MP, Kowatch RA, et al. Co-occurrence of bipolar and attention-deficit hyperactivity disorders in children. Bipolar Disord. 2006;8:710-720. 39. Kowatch RA, Fristad M, Birmaher B, et al. Treatment guidelines for children and adolescents with bipolar disorder. J Am Acad Child Adolesc Psychiatry. 2005;44:213-235. 40. Findling RL, McNamara NK, Stansbrey R, et al. Combination lithium and divalproex sodium in pediatric bipolar symptom re-stabilization. J Am Acad Child Adolesc Psychiatry. 2006;45:142-148. 41. Findling RL, McNamara NK, Youngstrom EA, et al. Double-blind 18month trial of lithium versus divalproex maintenance treatment in pediatric bipolar disorder. J Am Acad Child Adolesc Psychiatry. 2005;44: 409-417. 42. Sproule B. Lithium in bipolar disorder: Can drug concentrations predict therapeutic effect? Clin Pharmacokinet. 2002;41:639-660. 43. Kilbourne AM, Post EP, Bauer MS, et al. Therapeutic drug and cardiovascular disease risk monitoring in patients with bipolar disorder. J Affect Disord. 2007;102:145-151. 44. Biederman J, Mick E, Wozniak J, et al. An open-label of ripseridone in children and adolescents with bipolar disorder. J Child Adolesc Psychopharmacol. 2005;15:311-317. Join Pediatric Healthcare Professionals & Work Together to Achieve Common Goals The National Association of Pediatric Nurse Practitioners (NAPNAP) is the professional home for pediatric nurse practitioners (PNPs) and other advanced practice nurses who care for children. Member Benefits • Access to employment opportunities through the NAPNAP Career Connection • Quality educational content through PNPSourCESM—NAPNAP's online learning community • Comprehensive and quality educational sessions through providers of continuing nursing education • FREE subscriptions to the Journal of Pediatric Health Care magazine, the Pediatric Nurse Practitioner newsletter, and Pediatric News Visit www.napnap.org to apply online. COUNSELING POINTS™ 12 http://us.gsk.com/products/assets/us_dexedrine.pdf http://us.gsk.com/products/assets/us_dexedrine.pdf http://www.napnap.org

Table of Contents Feed for the Digital Edition of Counseling Points - January 2009

Counseling Points - January 2009

For optimal viewing of this digital publication, please enable JavaScript and then refresh the page. If you would like to try to load the digital publication without using Flash Player detection, please click here.